Mission Pharmacal Company announced that Binosto (alendronate sodium) effervescent tablet for buffered oral solution is now available for the treatment of osteoporosis in postmenopausal women, and to increase bone mass in men with osteoporosis. Binosto is an alternative to patients who prefer not to swallow tablets, suffer with dysphagia, or have other medical difficulties swallowing pills.
Binosto, a bisphosphonate, is a specific inhibitor of osteoclast-mediated bone resorption. It acts as a chelator of calcium and has a high binding affinity for mineralized bone.
Binosto is available as 70mg strawberry-flavored effervescent tablets in a 4-count pack.
For more information call (210) 696-8400 or visit www.binosto.com.